Most breast cancers are estrogen receptor-positive, meaning that signals received from estrogen, a hormone, promote the growth of the tumors. To stop these cancers from spreading, estrogen inhibitors are usually prescribed. But what happens when tumors develop treatment resistance? Studies suggest that “approximately 70 percent” of all breast cancers are estrogen receptor-positive (ER-positive). These types of cancer are typically treated with drugs — such as tamoxifen and fulvestrant — that either lower the levels of the hormone or inhibit the estrogen receptors to prevent the tumors from spreading. This is known as endocrine therapy. However, around a third of the people treated with these drugs develop resistance to them, which negatively impacts their chances of survival. The mechanisms that underlie the tumors’ resistance to therapy is not well understood and currently poses a major challenge. Recently, however, specialists from the Dana-Farber Cancer Institute in Boston, MA, have made significant progress in uncovering what exactly happens in the bodies of people in whom endocrine therapy does not work. Dr. Myles Brown — the director of the Center for Functional Cancer Epigenetics at the Institute — and his colleagues investigated how certain gene mutations render cancer cells more resilient, facilitating metastasis. Their… Read full this story
- Infectious diseases lead to cancer
- Infectious diseases a major cancer factor
- Prostate cancer gene map points way to targeted drugs
- Social Headlines December 12
- Vietnam ranks 12th among countries suffering most from TB
- The Benefits Of Watercress
- Who will intervene? Germ War: the US Record
- Social News Headlines 15/4
Why do some breast cancers become treatment-resistant? have 240 words, post on www.medicalnewstoday.com at November 29, 1999. This is cached page on xBlogs. If you want remove this page, please contact us.